OSR Health trading halted as Nasdaq delisting appeal set
OSR Health, Inc. (OSRH) reports that a Nasdaq Hearings Panel has scheduled a hearing for September 29, 2026 at 10:00 a.m. Eastern Time regarding the company’s appeal of a Nasdaq staff determination to delist its securities.
Rhea-AI Filing Summary
OSR Health, Inc. (OSRH) reports that a Nasdaq Hearings Panel has scheduled a hearing for September 29, 2026 at 10:00 a.m. Eastern Time regarding the company’s appeal of a Nasdaq staff determination to delist its securities. A timely hearing request was submitted on August 25, 2026, which stayed the filing of a Form 25-NSE and therefore the formal delisting from Nasdaq, but did not prevent the suspension of trading in OSR Health’s securities that took effect at the opening of business on August 26, 2026. The company is preparing a comprehensive plan to regain and sustain compliance with Nasdaq’s continued listing requirements and intends to advocate for continued listing, while cautioning that there can be no assurance the Panel will grant its request or that compliance will be regained.
Positive
- None.
Negative
- Trading in OSRH securities suspended on August 26, 2026, and the company warns there is no assurance the Nasdaq Hearings Panel will grant continued listing or that Nasdaq listing requirements will be regained.
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Hearing date and time: September 29, 2026 at 10:00 a.m. Eastern Time
Trading suspension effective date: August 26, 2026
Hearing request date: August 25, 2026
+2 more
5 metrics
Hearing date and time
September 29, 2026 at 10:00 a.m. Eastern Time
Scheduled Nasdaq Hearings Panel session on the company’s appeal
Trading suspension effective date
August 26, 2026
Suspension of trading in the company’s securities at the opening of business
Hearing request date
August 25, 2026
Date the company submitted its hearing request to appeal the delisting determination
Common stock par value
$0.0001 per share
Par value of OSR Health, Inc. common stock
Warrant exercise price
$11.50 per share
Exercise price of redeemable warrants for OSR Health common stock
Key Terms
Nasdaq Hearings Panel, Form 25-NSE, continued listing requirements, forward-looking statements
4 terms
Nasdaq Hearings Panel regulatory
"the Nasdaq Hearings Panel (the “Panel”) has scheduled the Company’s hearing"
A Nasdaq hearings panel is a group of experts that reviews cases when a company's stock listing is at risk of being removed from the exchange. They evaluate whether the company has met certain standards and determine if it can keep trading on Nasdaq. This process matters to investors because it can affect a company's ability to raise money and maintain credibility in the market.
Form 25-NSE regulatory
"stayed the filing of a Form 25-NSE, and therefore the formal delisting"
Form 25‑NSE is an official filing used to notify the stock exchange that a company’s securities are being removed from trading on that exchange, similar to handing in a key when a shop closes. Investors care because removal ends public trading on that venue, often cutting liquidity and making it harder to buy or sell shares, which can affect a stock’s price and how quickly investors can access cash or exit positions.
continued listing requirements regulatory
"regain and sustain compliance with the applicable Nasdaq continued listing requirements"
Rules a stock exchange sets that a publicly traded company must keep meeting to stay listed and tradable on that exchange, such as minimum share price, market value, timely financial reports, and basic governance practices. Like a club’s membership rules, they matter because falling short can lead to warnings, penalties or removal from the exchange, which can cut liquidity, hurt share value and increase the risk for investors.
forward-looking statements regulatory
"contains forward-looking statements within the meaning of the federal securities laws"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
FAQ
What Nasdaq action does OSR Health, Inc. (OSRH) disclose in this 8-K?
OSR Health discloses that Nasdaq has scheduled a Hearings Panel session on September 29, 2026 to review the company’s appeal of a staff delisting determination and its request for continued listing of its securities on Nasdaq.
When was trading in OSRH securities suspended on Nasdaq?
Trading in OSR Health’s securities was suspended on Nasdaq at the opening of business on August 26, 2026, following a staff delisting determination that the company has appealed to the Nasdaq Hearings Panel.
Is OSR Health (OSRH) already formally delisted from Nasdaq?
No. OSR Health states that its timely hearing request on August 25, 2026 stayed the filing of a Form 25-NSE, and therefore stayed the formal delisting from listing and registration on Nasdaq pending the Hearings Panel’s decision.
What does OSR Health plan to present to the Nasdaq Hearings Panel?
OSR Health is preparing a presentation that will include a comprehensive plan to regain and sustain compliance with applicable Nasdaq continued listing requirements and intends to advocate vigorously for continued listing of its securities.
Does OSR Health guarantee that OSRH will remain listed on Nasdaq?
No. OSR Health cautions that there can be no assurance the Nasdaq Hearings Panel will grant its request for continued listing or that the company will regain or maintain compliance with Nasdaq’s listing requirements.
What are the key details of OSR Health’s listed securities mentioned?
OSR Health lists common stock, par value $0.0001 per share (symbol OSRH), and redeemable warrants (symbol OSRHW) exercisable for common shares at an exercise price of $11.50 per share, both on The Nasdaq Stock Market LLC.
AI-generated analysis. How Rhea-AI works. Not financial advice.
